The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Peter A. J. Forsyth
Honoraria - Abbvie; BTG; Novocure
Consulting or Advisory Role - Abbvie; BTG; Novocure; ZIOPHARM Oncology
Travel, Accommodations, Expenses - Abbvie; BTG; Novocure; ZIOPHARM Oncology
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Christopher D. Lao
Research Funding - Bristol-Myers Squibb; Merck; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Stergios J. Moschos
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen; Genentech/Roche; Lexicon (Inst); Merck Sharp & Dome; Pharmacyclics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dome; Novartis
 
Omid Hamid
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Novartis; Sanofi/Regeneron
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); NextCure (Inst); Novartis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Polynoma (Inst); Regeneron (Inst); Roche (Inst)
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Karl D. Lewis
Honoraria - Array BioPharma; Incyte
Consulting or Advisory Role - Array BioPharma; Merck; Regeneron; Roche
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Roche/Genentech (Inst)
 
Reena Parada Thomas
Consulting or Advisory Role - Novocure
Research Funding - Bristol-Myers Squibb (Inst)
 
John A. Glaspy
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Sekwon Jang
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb
 
Alain Patrick Algazi
Stock and Other Ownership Interests - OncoSec; Valitor
Consulting or Advisory Role - Array BioPharma; OncoSec; Valitor
Research Funding - Acerta Pharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst); Oncosec (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - OncoSec
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Merck; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Anna C. Pavlick
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Merck; Novartis; Regeneron; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst); Millennium (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Regeneron; Sanofi/Regeneron
 
Marc S. Ernstoff
Stock and Other Ownership Interests - GE Healthcare
Consulting or Advisory Role - Bristol-Myers Squibb; Celyad; EMD Serono; Lion Biotechnologies; Omniseq
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merrimack (Inst)
 
David A. Reardon
Honoraria - Abbvie; Advantagene; Agenus; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; EMD Serono; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Merck; Merck KGaA; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Agenus; Bristol-Myers Squibb; Cavion; Celldex; EMD Serono; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Merck; Merck KGaA; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Omniox; Tragara (Inst)
 
Agnes Balogh
Employment - Bristol-Myers Squibb
 
Jasmine I. Rizzo
Employment - Bristol-Myers Squibb
 
Kim Allyson Margolin
Consulting or Advisory Role - Guidepoint Global; ImaginAb; Iovance Biotherapeutics; Nektar; Pyxis
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Genentech/Roche (Inst); Oncolytics